PMID- 35739427
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220715
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 101
IP  - 8
DP  - 2022 Aug
TI  - Comparable clinical outcomes of haploidentical hematopoietic stem cell 
      transplantation in patients with hepatitis-associated aplastic anemia and 
      non-hepatitis-associated aplastic anemia.
PG  - 1815-1823
LID - 10.1007/s00277-022-04885-w [doi]
AB  - Hepatitis-associated aplastic anemia (HAAA), a rare subtype of aplastic anemia 
      (AA), is defined as bone marrow failure occurring after acute hepatitis. Severe 
      HAAA requires immunosuppressive therapy (IST) or hematopoietic stem cell 
      transplantation (HSCT) as lifesaving treatment. The outcomes of HAAA patients who 
      underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT) 
      have not been systematically evaluated. We retrospectively compared the 
      characteristics of 15 patients with HAAA and 60 non-hepatitis-associated aplastic 
      anemia (non-HAAA) patients, all 75 of whom underwent haplo-HSCT in our hospital 
      between January 2006 and October 2021. The median ages of the patients were 
      18 years old (range, 3-36) for HAAA patients and 13 years (range, 2-45) for 
      non-HAAA patients (p = 0.693). The median time for neutrophil engraftment was 
      14 days (range, 11-22) in the HAAA group and 12 days (range, 10-21) in the 
      non-HAAA group (p = 0.363). At the time of analysis, 15 HAAA patients and 58 
      non-HAAA patients were alive, and their median follow-up times were 37 (range, 
      3-87) months and 31 (range, 2-110) months (p = 0.347), respectively. There were 
      no significant differences in the three-year overall survival (OS) rates (100% 
      vs. 96.7 +/- 0.33%, P = 0.638) or liver event-free survival (LEFS) (80.0 +/- 0.17% 
      vs. 76.7 +/- 0.19%, P = 0.747) between the two groups. Despite the small number of 
      HAAA patients due to the rarity of the disease, these results, such as the 
      similar incidence rates of 3-year OS and fewer liver events than expected, 
      suggest that haplo-HSCT is a feasible treatment for HAAA a when there are no 
      human leukocyte antigen (HLA)-matched donors available and has a low risk of 
      transplant-related mortality and complications.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Ma, Xiaodi
AU  - Ma X
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Zuo, Yangyang
AU  - Zuo Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Xu, Zhengli
AU  - Xu Z
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Cheng, Yifei
AU  - Cheng Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Han, Tingting
AU  - Han T
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Suo, Pan
AU  - Suo P
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Sun, Yuqian
AU  - Sun Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Tang, Feifei
AU  - Tang F
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Wang, Fengrong
AU  - Wang F
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Yan, Chenhua
AU  - Yan C
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Chen, Yuhong
AU  - Chen Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Zhang, Xiaohui
AU  - Zhang X
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Liu, Kaiyan
AU  - Liu K
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
FAU - Huang, Xiaojun
AU  - Huang X
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China.
AD  - Peking-Tsinghua Centre for Life Sciences, Beijing, China.
FAU - Xu, Lanping
AU  - Xu L
AUID- ORCID: 0000-0002-0267-1081
AD  - National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory 
      of Hematopoietic Stem Cell Transplant, Peking University People's Hospital, 
      Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng 
      District, 100044, Beijing, China. lpxu_0415@sina.com.
LA  - eng
GR  - 82100227/National Natural Science Foundation of China/
GR  - 81621001/Foundation for Innovative Research Groups of the National Natural 
      Science Foundation of China/
PT  - Journal Article
DEP - 20220623
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Anemia, Aplastic
MH  - Child
MH  - Child, Preschool
MH  - *Graft vs Host Disease/complications
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Hepatitis/complications/therapy
MH  - *Hepatitis A
MH  - Humans
MH  - Retrospective Studies
MH  - Transplantation Conditioning/methods
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Haploidentical hematopoietic stem cell transplant
OT  - Hepatitis-associated aplastic anemia
OT  - Severe aplastic anemia
OT  - Survival
EDAT- 2022/06/24 06:00
MHDA- 2022/07/16 06:00
CRDT- 2022/06/23 23:36
PHST- 2022/03/29 00:00 [received]
PHST- 2022/06/12 00:00 [accepted]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/06/23 23:36 [entrez]
AID - 10.1007/s00277-022-04885-w [pii]
AID - 10.1007/s00277-022-04885-w [doi]
PST - ppublish
SO  - Ann Hematol. 2022 Aug;101(8):1815-1823. doi: 10.1007/s00277-022-04885-w. Epub 
      2022 Jun 23.